Option Care Health (NASDAQ:OPCH) Releases FY 2025 Earnings Guidance

Option Care Health (NASDAQ:OPCH - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.610-1.700 for the period, compared to the consensus EPS estimate of 1.630. The company issued revenue guidance of $5.4 billion-$5.6 billion, compared to the consensus revenue estimate of $5.4 billion.

Option Care Health Stock Up 2.4 %

NASDAQ OPCH traded up $0.78 during trading hours on Friday, reaching $32.95. 3,358,100 shares of the company traded hands, compared to its average volume of 1,827,653. The stock has a market capitalization of $5.41 billion, a PE ratio of 27.69, a PEG ratio of 2.30 and a beta of 1.07. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. Option Care Health has a 12 month low of $21.39 and a 12 month high of $35.53. The company has a 50 day moving average of $33.34 and a two-hundred day moving average of $28.83.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the firm earned $0.26 earnings per share. The company's revenue for the quarter was up 16.3% compared to the same quarter last year. As a group, equities analysts expect that Option Care Health will post 1.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OPCH. Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a report on Wednesday. UBS Group upgraded Option Care Health from a "neutral" rating to a "buy" rating and lifted their target price for the company from $38.00 to $40.00 in a research note on Wednesday. Jefferies Financial Group raised Option Care Health from a "hold" rating to a "buy" rating and raised their price target for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. Bank of America upgraded Option Care Health from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $36.00 target price on shares of Option Care Health in a research report on Tuesday, April 22nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $35.50.

Insider Buying and Selling

In other news, insider Michael Bavaro sold 30,996 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the transaction, the insider now directly owns 44,974 shares in the company, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.64% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.